Summary & Overview
HCPCS J1439: Ferric Carboxymaltose Injection, 1 mg
HCPCS Level II code J1439 denotes an injection of ferric carboxymaltose measured per 1 mg and is used to bill for intravenous iron therapy. This code matters nationally because intravenous iron is an important treatment for patients with iron deficiency anemia when oral therapy is ineffective or intolerable; accurate coding affects access to infusion therapies, claims adjudication, and cost reporting across outpatient settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, typical sites of service where ferric carboxymaltose is administered, and common billing practices tied to this HCPCS Level II code. The publication outlines benchmarks for utilization and reimbursement structures, summarizes recent policy updates affecting infusion therapies and injectable iron products, and provides clinical context about indications for intravenous ferric carboxymaltose.
The content focuses on national-level implications for providers, payers, and administrators, highlighting coding considerations, billing workflows, and areas where policy changes may influence coverage and payment for J1439. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J1439 represents an injection of ferric carboxymaltose billed per 1 mg. This code describes the administered formulation of intravenous iron used to treat iron deficiency when oral iron is inadequate or not tolerated.
Service Type: Intravenous iron infusion/injection
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or physician office
Clinical & Coding Specifications
Clinical Context
A 58-year-old female with chronic iron-deficiency anemia secondary to heavy uterine bleeding presents to an outpatient infusion center for intravenous iron repletion. Oral iron was poorly tolerated and ineffective. After outpatient evaluation, including hemoglobin, ferritin, and transferrin saturation, the treating hematology or primary care clinician orders intravenous ferric carboxymaltose. The medication is billed as J1439 per milligram; dosing is calculated based on the patient’s weight and hemoglobin deficit. The clinical workflow includes: pre-infusion vitals and allergy review, informed consent, placement of an IV catheter, administration of the calculated dose of ferric carboxymaltose over the recommended infusion time, monitoring for hypersensitivity reactions during and for a period after infusion, documentation of lot number and amount administered, and discharge instructions. Typical sites of service are outpatient infusion centers, hospital outpatient departments, ambulatory surgery centers when available, and physician office-based infusion suites. Common clinicians involved include hematologists, obstetrician-gynecologists (for menorrhagia-related anemia), family medicine or internal medicine clinicians managing anemia, and trained infusion nurses who administer and monitor the infusion.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |